Study on the Effects of Combined Use of Denosumab,Calcium Carbonate D3,and Calcitriol on Bone Density and Bone Metabolism Indicators in Elderly Patients with Osteoporosis
WEN Yan
WANG Yue
LI Jianghua
CHEN Jialin
JIAO JingJing
Abstract：Objective To investigate the clinical efficacy of denosumab,calcium carbonate D3,and calcitriol in elder-ly patients with osteoporosis.Methods A total of 98 elderly patients with osteoporosis admitted to Hebei PetroChina Central Hospital from January 2021 to January 2023 were enrolled.Patients were randomly divided into a control group(n=49)and an observation group(n=49)using a random number table.The control group received calcium carbonate D3 and calcitriol,while the observation group received additional denosumab.Post-treatment comparisons included bone mineral density,bone metab-olism indicators,lumbar pain,lumbar dysfunction,and adverse reactions.Results The observation group showed significantly higher overall efficacy than the control group(P<0.05).Post-treatment lumbar spine bone mineral density(0.82±0.17)g/cm2 and hip bone mineral density(0.78±0.17)g/cm2 in the observation group were significantly higher than those in the control group(0.68±0.14)g/cm2 and(0.63±0.14)g/cm2.Additionally,the levels of bone alkaline phosphatase(114.12±11.85)U/L,type I collagen carboxyl-terminal peptide(575.23±50.84)pg/mL,tartrate-resistant acid phosphatase 5b(3.63±0.97)U/L,and β-collagen special sequence(0.23±0.11)μg/L in the observation group were significantly lower than those in the control group(207.58±12.35)U/L,(612.13±62.03)pg/mL,(5.93±1.11)U/L,and(0.36±0.13)μg/L.Meanwhile,the osteocalcin level(5.25±0.76)μg/L in the observation group was higher than that in the control group(3.53±0.63)μg/L,with all differences be-ing statistically significant(P<0.05).The Visual Analogue Scale(VAS)score and Oswestry Disability Index(ODI)score in the observation group were significantly lower than those in the control group(P<0.05).However,there was no statistically signifi-cant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Denosumab combined with calcium carbonate D3 and calcitriol effectively improved bone mineral density,metabolism markers,pain,and in elderly osteo-porosis patients,demonstrating good safety.
Keywords：Elderly osteoporosisDisumabCalcium carbonate D3CalcitriolAdverse reactions
Publication Date：2025-03-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 41-44 )